Vol. 4 No. 2 (2024): February
Reimbursement Reviews

Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

decorative image of the issue cover

Published February 9, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta):
    • Elexacaftor 100 mg–tezacaftor 50 mg–ivacaftor 75 mg (granules) and ivacaftor 75 mg (granules), oral
    • Elexacaftor 80 mg–tezacaftor 40 mg–ivacaftor 60 mg (granules) and ivacaftor 59.5 mg (granules), oral

      Patients aged 6 years and older:

    • Elexacaftor 50 mg–tezacaftor 25 mg–ivacaftor 37.5 mg (combination tablet) and ivacaftor 75 mg (tablet), oral
    • Elexacaftor 100 mg–tezacaftor 50 mg–ivacaftor 75 mg (combination tablet) and ivacaftor 150 mg (tablet), oral.
  • Indication: For the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.